Is Foundayo the same as orforglipron?

Yes. Foundayo is the brand name; orforglipron is the generic. Eli Lilly markets it.

Eli Lilly and Company. It was approved by the FDA on April 1, 2026.

How does Foundayo compare to orforglipron in clinical trials?

They are the same molecule. The 17.2 mg approved tablet is bioequivalent to the 36 mg orforglipron capsule used in the ATTAIN-1 Phase 3 trial.

What is the orforglipron mechanism of action?

Orforglipron is a small-molecule, non-peptide agonist of the GLP-1 receptor. It mimics GLP-1 to slow gastric emptying, reduce appetite, and improve glucose-dependent insulin secretion.

Did orforglipron pass Phase 3?

Yes. The ATTAIN-1 Phase 3 trial showed 12.4% average weight loss at 72 weeks at the highest dose versus 0.9% on placebo, supporting FDA approval in April 2026.

How is Foundayo different from Rybelsus?

Foundayo is a small molecule that absorbs without food or water restrictions and can be taken any time of day. Rybelsus is a peptide that requires empty stomach, 4 oz water, and a 30-minute wait. Foundayo is approved for weight loss; Rybelsus is approved for type 2 diabetes.

How is Foundayo different from injectable Wegovy?

Foundayo is a daily oral tablet; Wegovy is a weekly subcutaneous injection. Wegovy produces larger average weight loss (about 15% vs 11 to 12%) but requires needles and refrigeration.

How do I get Foundayo?

Through a prescription from a clinician, filled through LillyDirect or a retail pharmacy. You need a BMI of 30 or higher, or 27 plus a weight-related condition.

Is there a Foundayo app or Foundayo tracker?

Lilly does not publish a dedicated Foundayo app at launch. Most patients use generic GLP-1 tracker apps or Apple Health to log dose, weight, and side effects.

Do I need to take Foundayo with food?

No. Foundayo can be taken with or without food, with or without water, any time of day. That is one of its main practical advantages over Rybelsus.

What lifestyle changes work best on Foundayo?

Prioritize protein (about 0.8 to 1.0 g per pound of goal weight), resistance training two to three times weekly, and consistent hydration to protect lean mass and manage GI side effects.

Can I switch from Wegovy or Zepbound to Foundayo?

Yes, with prescriber supervision. You stop the injection and start Foundayo at the 0.8 mg starting dose, then titrate up. Do not overlap GLP-1 agents.

Is Foundayo covered by insurance?

Coverage is expanding through 2026. Commercially insured eligible patients can pay as low as $25 per month through LillyDirect. Self-pay starts around $149 per month at the lowest dose. Check your specific plan.

What Is Foundayo?

Summary: Foundayo is the brand name for orforglipron, Eli Lilly's once-daily oral small-molecule GLP-1 receptor agonist approved by the FDA on April 1, 2026 for chronic weight management in adults with obesity or overweight plus a weight-related condition.

This content is for informational purposes only and is not medical advice. Always consult a qualified healthcare provider before starting, changing, or stopping any medication.

Foundayo is the brand name Eli Lilly uses for orforglipron, a once-daily oral GLP-1 receptor agonist tablet for weight loss. The FDA approved it on April 1, 2026 for chronic weight management in adults with obesity, or in adults with overweight who also have a weight-related medical condition ^[1]. It is the second daily oral medication approved for obesity in the United States, after oral semaglutide. The difference that matters: Foundayo is a small-molecule, non-peptide GLP-1, so you can take it any time of day, with or without food, with no water restriction.

Below is what Foundayo actually is, how it dosed, what the trial data shows, and how it lines up against Rybelsus and weekly Wegovy.

The basics

Generic name: orforglipron. Pronunciation: fown-DAY-oh. Manufacturer: Eli Lilly and Company. Drug class: GLP-1 receptor agonist (small-molecule, non-peptide). Form: oral tablet. Dose strengths: 0.8, 2.5, 5.5, 9, 14.5, and 17.2 mg. Schedule: once daily, with or without food, any time of day. FDA approval: April 1, 2026 for chronic weight management ^[1]. Indication: adults with obesity (BMI ≥30), or adults with overweight (BMI ≥27) plus a weight-related condition such as type 2 diabetes, hypertension, or dyslipidemia. Used together with a reduced-calorie diet and increased physical activity.

What makes Foundayo different from other oral GLP-1s

Foundayo is a small-molecule, non-peptide GLP-1 receptor agonist. That single fact drives almost every practical difference between it and Rybelsus.

Rybelsus is oral semaglutide. Semaglutide is a peptide, and peptides break down in stomach acid before they can be absorbed. To get around that, Rybelsus is co-formulated with salcaprozate sodium (SNAC), an absorption enhancer, and you have to take it on an empty stomach with no more than 4 ounces of plain water, then wait at least 30 minutes before eating, drinking anything else, or taking other medications ^[5]. Miss any of those rules and absorption tanks.

Foundayo skips all of that. The small-molecule structure survives gastric acid intact and absorbs through the gut without an enhancer. You take the tablet, swallow it with whatever, and continue your day. That is the headline convenience win ^[1].

The other consequence of being a small molecule: the manufacturing economics are different. Peptide drugs require complex biological synthesis. Small molecules are made by traditional chemistry, which scales faster and cheaper. That is why orforglipron has been positioned for years as the GLP-1 that could be priced low enough to expand access at scale.

How Foundayo works

Foundayo mimics glucagon-like peptide-1 (GLP-1), a gut hormone released after eating. By binding the GLP-1 receptor, it does three things that drive weight loss:

Slows gastric emptying, so food sits in the stomach longer and satiety lasts longer.
Acts on appetite centers in the brain to reduce hunger and food noise.
Improves glucose handling by increasing insulin and decreasing glucagon in a glucose-dependent way, which is why it also lowers HbA1c in people with type 2 diabetes.

The mechanism is the same as injectable GLP-1s like Ozempic, Wegovy, and Trulicity. The molecule is just shaped to work as a daily oral pill instead of a weekly injection.

Dosing schedule

Foundayo follows a six-step titration. Each step lasts at least 30 days before you escalate, and the escalation is meant to give the gut time to adapt to slowed gastric emptying. Skipping ahead is a fast path to dropping out from nausea and vomiting.

Step	Dose	Minimum time on previous step
Starting dose	0.8 mg once daily	Start here
Step 2	2.5 mg once daily	30 days on 0.8 mg
Step 3	5.5 mg once daily	30 days on 2.5 mg
Step 4	9 mg once daily	30 days on 5.5 mg, if needed
Step 5	14.5 mg once daily	30 days on 9 mg, if needed
Step 6 (max)	17.2 mg once daily	30 days on 14.5 mg, if needed

Swallow tablets whole. Do not break, crush, or chew. If you miss a dose, take it as soon as you remember, but never take two doses in the same day. If you miss seven or more days in a row, call your prescriber before restarting; you may need to drop back a step to retitrate ^[1].

What the trials show

The pivotal data comes from Lilly's ATTAIN-1 Phase 3 trial in adults with obesity (NCT05869903), a 72-week placebo-controlled study ^[3]. The label-relevant results, using the FDA-approved tablet strengths:

Outcome at Week 72	Placebo	Foundayo 5.5 mg	Foundayo 9 mg	Foundayo 17.2 mg
Average body weight change	-2.1%	-7.4%	-8.3%	-11.1%
Estimated pounds lost	-4.8 lbs	-16.8 lbs	-18.7 lbs	-25.2 lbs

In the highest investigational dose arm of ATTAIN-1, 36 mg orforglipron capsules (equivalent to the approved 17.2 mg tablet) produced an average weight loss of 12.4 percent, roughly 27.3 pounds, versus 0.9 percent (2.2 pounds) on placebo at 72 weeks ^[1]. The trial also showed improvements in waist circumference, non-HDL cholesterol, triglycerides, and systolic blood pressure.

In a separate 72-week trial in adults with type 2 diabetes, average weight loss was 5.1 percent at 5.5 mg, 7 percent at 9 mg, and 9.6 percent at 17.2 mg, versus 2.5 percent on placebo ^[2].

For perspective: those numbers land Foundayo between Rybelsus (oral semaglutide, average roughly 8 to 10 percent at maximum 25 mg dose for obesity) and injectable Wegovy (semaglutide 2.4 mg weekly, average around 15 percent over 68 weeks in STEP-1). It is the strongest oral weight-loss medication on the market, and it is meaningfully weaker than the strongest injection.

Foundayo vs Rybelsus vs Wegovy injection

The three drugs in this comparison are all GLP-1 receptor agonists, but they differ in molecule type, route, dosing, and absorption rules. The table below is the practical cheat sheet.

Feature	Foundayo (orforglipron)	Rybelsus (oral semaglutide)	Wegovy (semaglutide injection)
Molecule	Small-molecule, non-peptide	Peptide + SNAC enhancer	Peptide
Route	Oral tablet	Oral tablet	Weekly subcutaneous injection
Frequency	Once daily, any time	Once daily, empty stomach	Once weekly
Food/water rules	None, take with or without food	Empty stomach, ≤4 oz water, wait 30 min	None
Max approved dose	17.2 mg	14 mg (diabetes); 25 mg (obesity, Wegovy oral)	2.4 mg weekly
Approved use for weight loss	Yes (April 2026)	Wegovy oral approved; Rybelsus is diabetes-only	Yes
Average weight loss at max dose	About 11 to 12% at 72 weeks	About 8 to 10% at 72 weeks (oral 25 mg)	About 15% at 68 weeks (STEP-1)
Storage	Room temp, 68 to 77°F	Room temp	Refrigerated until first use
Manufacturer	Eli Lilly	Novo Nordisk	Novo Nordisk

The choice between the three usually comes down to three questions. Do you want a needle? If no, Foundayo or Rybelsus. Do you want to skip the fasted-dose ritual? If yes, Foundayo. Do you want the maximum proven weight loss? Weekly injectable Wegovy still wins on that dimension.

Side effects

The side effect profile mirrors other GLP-1 receptor agonists, because the mechanism is the same. The most common are gastrointestinal and dose-dependent: nausea, abdominal pain, heartburn, constipation, diarrhea, vomiting, indigestion, bloating, belching, and gas. Headache, fatigue, and hair loss also show up in the label ^[1].

Serious side effects to know about:

Pancreatitis. Severe, persistent abdominal pain that may radiate to the back. Stop the drug and call your prescriber.
Severe GI problems. Including gastroparesis-like symptoms.
Dehydration and kidney injury from persistent vomiting or diarrhea.
Hypoglycemia when combined with insulin or sulfonylureas.
Gallbladder disease. Same class effect seen across GLP-1s.
Diabetic retinopathy complications in people with type 2 diabetes.
Allergic reactions, including angioedema.
Pulmonary aspiration during anesthesia. Tell every clinician before any procedure with sedation.

Foundayo carries a boxed warning for thyroid C-cell tumors. In rodents, GLP-1 receptor agonists caused medullary thyroid carcinoma. Whether they do in humans is unknown, but as a precaution Foundayo is contraindicated in anyone with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) ^[1].

Who should not take Foundayo

Personal or family history of medullary thyroid carcinoma.
Multiple Endocrine Neoplasia syndrome type 2.
Severe liver impairment (Child-Pugh Class C).
Known hypersensitivity to orforglipron or any tablet ingredient.
Pregnancy. Foundayo may harm the fetus. Discontinue if you become pregnant.
Breastfeeding is not recommended during treatment.
Concurrent use with other GLP-1 receptor agonists (no stacking Foundayo with Wegovy, Ozempic, Mounjaro, Zepbound, etc.).

How to get Foundayo

Foundayo is prescription-only. Lilly is distributing it through LillyDirect, the same direct-to-patient platform used for Zepbound vials. Commercially insured patients with coverage start at around $25 per month. Cash-pay self-pay pricing starts at $149 per month for the lowest 0.8 mg dose, and some eligible Medicare Part D beneficiaries can access Foundayo for $50 per month beginning July 1, 2026 ^[1]. Retail pharmacy availability is rolling out in 2026; ask your prescriber and your pharmacy what is in stock locally, because pricing and channel access are still changing.

To get a prescription you need a clinician visit (in person or telehealth) and a diagnosis that matches the FDA-approved indication: BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity. A LillyDirect telehealth consult is one route. Your primary care physician, endocrinologist, or obesity medicine specialist is another. Many telehealth weight-loss platforms have added Foundayo to their formulary alongside Wegovy and Zepbound.

Lifestyle changes on Foundayo

The FDA label and every trial protocol pair Foundayo with a reduced-calorie diet and increased physical activity. That is not boilerplate. The trial weight-loss numbers above are on top of lifestyle changes, not instead of them. Three concrete moves that pay off:

Protein at every meal. GLP-1s suppress appetite, which is the point, but they also make it easy to undereat protein. Aim for 0.8 to 1.0 g of protein per pound of goal body weight per day to protect lean mass while you lose fat. The published trial data show greater fat-mass loss than lean-mass loss with orforglipron, but that ratio holds up better when protein is adequate.
Resistance training two to three times per week. Same reason: preserve lean mass during a calorie deficit.
Hydration discipline. GI side effects can deplete fluids faster than you notice. Drink water on a schedule, not just when thirsty.

If you use a Foundayo tracker or a generic GLP-1 tracker app to log weight, doses, and side effects, the data tends to make titration conversations with your prescriber more productive. Lilly has not released a dedicated Foundayo tracker app at launch, but most patients use Apple Health, MyFitnessPal, or third-party GLP-1 tracking apps that already support orforglipron logging.

Drug interactions worth flagging

Strong CYP3A4 inhibitors raise Foundayo levels. Cap the dose at 9 mg daily and avoid combinations that also inhibit OATP1B.
Strong CYP3A4 inducers lower Foundayo levels enough to compromise effect. Avoid.
Simvastatin. Foundayo increases simvastatin exposure. Do not exceed simvastatin 20 mg once daily.
Insulin and sulfonylureas raise hypoglycemia risk. Your prescriber may lower those doses when starting Foundayo.
Oral medications generally. Delayed gastric emptying can change the absorption timing of other oral drugs. Review your full medication list when you start.

How Foundayo lines up against Wegovy injection in plain terms

If your priority is maximum weight loss with one shot per week and you do not mind needles, Wegovy is still the heavier hitter at roughly 15 percent average weight loss at its 2.4 mg dose. If your priority is avoiding injections entirely and you want a pill you can swallow with coffee on the way out the door, Foundayo is the strongest option that exists at roughly 11 to 12 percent average weight loss at the 17.2 mg dose. Rybelsus is the older oral, useful if you have already tolerated semaglutide and want to stay on it, but the fasted-dose rules make adherence harder for most people in practice.

The cost calculation depends on your insurance. For cash-pay patients, oral small-molecule manufacturing should make Foundayo less expensive over time than peptide injections, but launch pricing is still in flux. Check LillyDirect and your pharmacy directly rather than relying on coverage summaries written before April 2026.

Common questions about Foundayo

Is Foundayo the same as orforglipron?: Yes. Foundayo is the brand name; orforglipron is the generic. Eli Lilly markets it.
Who makes Foundayo?: Eli Lilly and Company. It was approved by the FDA on April 1, 2026.
How does Foundayo compare to orforglipron in clinical trials?: They are the same molecule. The 17.2 mg approved tablet is bioequivalent to the 36 mg orforglipron capsule used in the ATTAIN-1 Phase 3 trial.
What is the orforglipron mechanism of action?: Orforglipron is a small-molecule, non-peptide agonist of the GLP-1 receptor. It mimics GLP-1 to slow gastric emptying, reduce appetite, and improve glucose-dependent insulin secretion.
Did orforglipron pass Phase 3?: Yes. The ATTAIN-1 Phase 3 trial showed 12.4% average weight loss at 72 weeks at the highest dose versus 0.9% on placebo, supporting FDA approval in April 2026.
How is Foundayo different from Rybelsus?: Foundayo is a small molecule that absorbs without food or water restrictions and can be taken any time of day. Rybelsus is a peptide that requires empty stomach, 4 oz water, and a 30-minute wait. Foundayo is approved for weight loss; Rybelsus is approved for type 2 diabetes.
How is Foundayo different from injectable Wegovy?: Foundayo is a daily oral tablet; Wegovy is a weekly subcutaneous injection. Wegovy produces larger average weight loss (about 15% vs 11 to 12%) but requires needles and refrigeration.
How do I get Foundayo?: Through a prescription from a clinician, filled through LillyDirect or a retail pharmacy. You need a BMI of 30 or higher, or 27 plus a weight-related condition.
Is there a Foundayo app or Foundayo tracker?: Lilly does not publish a dedicated Foundayo app at launch. Most patients use generic GLP-1 tracker apps or Apple Health to log dose, weight, and side effects.
Do I need to take Foundayo with food?: No. Foundayo can be taken with or without food, with or without water, any time of day. That is one of its main practical advantages over Rybelsus.
What lifestyle changes work best on Foundayo?: Prioritize protein (about 0.8 to 1.0 g per pound of goal weight), resistance training two to three times weekly, and consistent hydration to protect lean mass and manage GI side effects.
Can I switch from Wegovy or Zepbound to Foundayo?: Yes, with prescriber supervision. You stop the injection and start Foundayo at the 0.8 mg starting dose, then titrate up. Do not overlap GLP-1 agents.
Is Foundayo covered by insurance?: Coverage is expanding through 2026. Commercially insured eligible patients can pay as low as $25 per month through LillyDirect. Self-pay starts around $149 per month at the lowest dose. Check your specific plan.